THURSDAY, April 17, 2025 — Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease and related dementias (ADRDs) among people with…
What You Should Know: – Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone. – Orforglipron stands out as the first oral small … Read more
Science, Volume 388, Issue 6744, Page 241-242, April 2025.
It’s little secret that America has a weight problem. For decades, Americans have embraced and abandoned countless weight-loss strategies, including fad diets, that have proven ineffective long term. Despite our best efforts, more people are at risk of health complications resulting from obesity, including type 2 diabetes and heart disease. Related: UnitedHealth stock tumbles after Medicare Advantage … Read more
A daily pill from drugmaker Eli Lilly has shown similar effectiveness at helping people reduce blood sugar levels and lose weight compared to leading injectable GLP-1 drugs Mounjaro and Ozempic, the company announced. The once-daily pill, called orforglipron, helped patients with Type 2 diabetes during late-stage trials and has shown comparable safety results to the … Read more
In the current issue of JAMA Ophthalmology, Cai and colleagues report a small increase in the relative incidence of nonarteritic anterior ischemic optic neuropathy (NAION) due to semaglutide, a glucagonlike peptide 1 receptor agonist (GLP-1RA). The authors captured data from 14 databases within the Observational Health Data Sciences and Informatics network, which is an international … Read more
by Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC) Background Diabetes mellitus, particularly type 2 diabetes, is a growing health concern in low- and middle-income countries (LMICs). The potential impact of newer diabetes medications, such as glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, on insulin dosage … Read more
A new pill taken orally could be as effective for type 2 diabetes and weight loss as comparable injectable products, Eli Lilly announced Thursday.
